NOVARTIS SHINES, AWAY FROM THE LIMELIGHT (ADD; 16% UPSIDE)
08/12/25 -" Despite US tariff threats, drug pricing pressures and the persistent insistence from the US government to reshore manufacturing, the AV Big Pharmas (unweighted; +11% ytd) have fared decently in ..."
Pages
67
Language
English
Published on
08/12/25
You may also be interested by these reports :
08/12/25
Despite US tariff threats, drug pricing pressures and the persistent insistence from the US government to reshore manufacturing, the AV Big Pharmas ...
05/12/25
Against the backdrop of strong execution, with two outlook upgrades in 2025, backed by vigorous growth across all its focus areas (oncology, ...
28/11/25
Novo’s investors losing more weight than its patients
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...